Saturday 17 October 2026 Export SLGL’s income statement to Excel — free account

Sol-Gel Technologies Ltd.

Sol-Gel Technologies Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $19.4 million, up 68.0% from fiscal 2024. In the quarter to June 2026, revenue fell 96.6%, EPS fell 127.1% and free cash flow fell 8.76%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

64.25 4.45 −6.48%

Follow SLGL

Alert me

Market cap: $224.9M
P/E: 0.0×
Fwd P/E: −9.4×
Dividend yield: —
F-score: 6/9
Altman Z: −0.53
Beneish M: −3.60
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 11.22

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	2	6	3	2	1	—	2	—	3	2	3	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 59.65%

Capital & Financial Ratios $m

Market Cap 224.92

Revenue 1.80

Net Income (13.53)

Free Cash Flow (21.27)

Net Debt (47.93)

Current Ratio 10.37

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (9.44)

P/S ratio 117.08

P/B ratio 4.37

Past 5Y EPS Growth —

This Y EPS Growth (253.14%)

Next Y EPS Growth (16.88%)

Next Y revenue growth (94.72%)

Next 5Y EPS Growth 28.57%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 93.27%

10-year low 10-year high

P/B against its own 10 years 81.39%

10-year low 10-year high

EV/Sales against its own 10 years 93.27%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	28	24	24	48
Receivables	0	4	2	1
Inventory	—	—	—	—
Other	10	0	—	—
	41	31	27	51

	2023	2024	2025	Q'26
Payables	0	1	1	1
ST’ Debt	—	—	—	—
Other	—	—	—	—
	5	5	6	5

Compound Annual Growth %

	10y	5y	3y
Sales	—	17.19%	70.92%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	0.00%	(14.81%)	(18.55%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	1	—	—	—
’25	1	17	0	1	19
’24	0	5	5	0	12
’23	0	1	0	0	2
’22	0	4	0	0	4
’21	1	1	9	21	31
’20	3	1	2	2	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(8)	—	—	—
’25	—	1	—	0	0
’24	—	(8)	—	(14)	(14)
’23	—	—	—	—	(18)
’22	—	—	—	—	(9)
’21	—	—	—	—	(8)
’20	—	—	—	—	(25)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(8)	—	—	—
’25	—	1	—	0	0
’24	—	(8)	—	(14)	(14)
’23	—	0	—	0	(18)
’22	—	0	—	0	(10)
’21	—	0	—	0	(8)
’20	—	0	—	0	(26)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(1.31)	(1.13)	—	—	—
’25	(3.20)	4.17	(2.13)	(1.07)	(2.19)
’24	(2.30)	0.70	(0.10)	(2.10)	(3.80)
’23	(4.10)	(2.20)	(2.10)	(1.70)	(10.10)
’22	(2.40)	(0.06)	(1.50)	(2.50)	(6.50)
’21	(1.80)	(3.50)	0.50	6.10	1.40
’20	(3.30)	(3.10)	(3.70)	(2.81)	(13.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	54.10	57.10	50.00	61.20	39.40	9.20	3.34	4.02	Analyst estimates 2026–2028 Powerpack
	High	—	—	164.80	210.00	178.45	166.90	85.10	57.10	16.50	52.26
People
People	Employees	47	49	56	61	65	53	55	36	34	28
	Revenue/emp, $m	0.00	0.00	0.00	0.38	0.13	0.59	0.07	0.04	0.34	0.69
Income, $m
Income, $m	Revenue	—	0	0	23	9	31	4	2	12	19
	Gross margin, %	0.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00	100.00
	EBT	(21)	(32)	(33)	(25)	(29)	3	(15)	(27)	(11)	(6)
	EBT margin, %	0.00	(18,142.53)	(25,738.76)	(107.30)	(333.94)	10.30	(384.32)	(1,752.77)	(91.70)	(31.60)
	Net income	(21)	(32)	(32)	(25)	(29)	3	(15)	(27)	(11)	(6)
	Depreciation	0	0	1	1	1	1	1	0	0	0
Per share, $
Per share, $	Revenue	0.00	0.28	0.07	11.72	3.89	13.56	1.68	0.57	4.14	6.96
	Earnings	(33.00)	(50.20)	(18.00)	(12.60)	(13.00)	1.40	(6.50)	(10.10)	(3.80)	(2.19)
	Cash flow	(29.40)	(38.30)	(13.13)	(11.52)	(11.18)	(3.33)	(4.10)	(6.55)	(4.99)	0.12
	Capex	(0.61)	(3.06)	(0.59)	(0.31)	(0.20)	(0.06)	(0.07)	(0.02)	0.00	0.00
	Free cash flow	(30.02)	(41.36)	(13.72)	(11.82)	(11.38)	(3.40)	(4.17)	(6.57)	(4.98)	0.12
	Book value	(49.82)	(83.78)	35.77	26.86	22.52	24.11	18.25	14.27	10.36	8.19
	Shares, m	1	1	2	2	2	2	2	3	3	3
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	52.86	0.00	0.00	0.00	0.00
	P/S	—	0.00	833.84	14.63	25.20	5.46	28.17	21.27	2.25	6.06
	P/B	—	0.00	1.68	6.39	4.35	3.07	2.59	0.86	0.90	5.15
	EV/Sales	—	0.00	859.75	15.28	29.37	6.85	39.56	45.30	5.84	8.19
	EV/FCF	—	(3.09)	(2.72)	(5.03)	(3.59)	(3.90)	(4.32)	(1.66)	(2.25)	(7.70)
Cash, $m
Cash, $m	Operating cash flow	(18)	(24)	(23)	(22)	(25)	(8)	(9)	(18)	(14)	0
	Capex	0	(2)	(1)	(1)	0	0	0	0	0	0
	Free cash flow	(19)	(26)	(25)	(23)	(26)	(8)	(10)	(18)	(14)	0
Balance, $m
Balance, $m	Working capital	(33)	(57)	61	49	47	45	40	37	26	21
	Total debt	37	65	—	1	1	1	1	—	—	—
	Net debt	30	60	(62)	(50)	(29)	(22)	(21)	(28)	(24)	(24)
	Shareholders’ equity	(31)	(53)	64	52	51	56	42	39	29	23
Returns, %
Returns, %	ROA	(216.04)	(240.06)	(75.77)	(37.58)	(48.63)	5.02	(25.77)	(59.27)	(26.08)	(18.63)
	ROIC	0.00	(259.63)	(1,090.04)	(777.13)	(85.60)	5.48	(48.15)	(171.82)	(152.12)	0.00
	ROE	96.94	75.13	(574.54)	(42.29)	(56.70)	6.05	(30.52)	(67.37)	(31.35)	(23.72)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
QTTB Q32 Bio Inc.	$231.3M	2.5×	— (loss-making)	−1,928.18% (below 0%: shrinking)	n/m	+71.13% (above 0%: growing)	100.00%	0.00%	Compare
FATE Fate Therapeutics, Inc.	$230.7M	— (loss-making)	— (loss-making)	+9.18% (above 0%: growing)	n/m	+8.96% (above 0%: growing)	100.00%	(1,495.39%)	Compare
LXEO Lexeo Therapeutics, Inc.	$226.6M	— (loss-making)	— (loss-making)	—	n/m	+35.58% (above 0%: growing)	0.00%	0.00%	Compare
SLGL Sol-Gel Technologies Ltd.	$224.9M	— (loss-making)	— (loss-making)	−96.58% (below 0%: shrinking)	n/m	−8.76% (below 0%: shrinking)	100.00%	(704.23%)
GLSI Greenwich LifeSciences, Inc.	$224.9M	— (loss-making)	—	—	n/m	+13.14% (above 0%: growing)	0.00%	0.00%	Compare
KROS Keros Therapeutics, Inc.	$220.1M	— (loss-making)	— (loss-making)	−99.83% (below 0%: shrinking)	n/m	+32.19% (above 0%: growing)	100.00%	0.00%	Compare
PLX Protalix BioTherapeutics, Inc.	$217.5M	10.9×	10.2×	+27.07% (above 0%: growing)	+2,280.95% (above 0%: growing)	−94.09% (below 0%: shrinking)	60.99%	23.48%	Compare
CAMP CAMP4 Therapeutics Corporation	$216.5M	— (loss-making)	— (loss-making)	+18.84% (above 0%: growing)	n/m	−23.90% (below 0%: shrinking)	100.00%	(752.11%)	Compare
PYXS Pyxis Oncology, Inc.	$215.3M	— (loss-making)	— (loss-making)	—	n/m	−5.46% (below 0%: shrinking)	100.00%	0.00%	Compare
Median of peers	$222.5M	—	—	+9.18%	—	+11.05%	100.00%	0.00%

All 614 Biotechnology stocks →